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Background: Although chemoprophylaxis remains an important strategy for preventing malaria in travellers, its
effectiveness may be compromised by lack of adherence. Inappropriate use of chemoprophylaxis is likely to
increase the risk of acquiring malaria, but may probably also worsen the severity of imported cases. The aim of
this study was to assess the impact of use of malaria chemoprophylaxis on clinical features and outcome of
imported malaria.
Methods: Demographic, clinical and laboratory data of patients included in the Rotterdam Malaria Cohort between
1998 and 2011 were systematically collected and analysed. Patients were classified as self-reported compliant or
non-compliant users or as non-users of chemoprophylaxis. Severe malaria was defined using the 2010 WHO criteria.
Results: Details on chemoprophylaxis were available for 559 of the 604 patients, of which 64.6% were non-users,
17.9% were inadequate users and 17.5% reported to be adequate users. The group of non-users was predominated
by patients with African ethnicity, partial immunity and people visiting friends and relatives. The majority contracted
Plasmodium falciparum malaria. In contrast, compliant users acquired non-falciparum malaria more frequently, had
significant lower P. falciparum loads on admission, shorter duration of hospitalization and significant lower odds for
severe malaria as compared with non-users. Patients with P. falciparum malaria were more likely to have taken their
chemoprophylaxis less compliantly than those infected with non-P. falciparum species. Multivariate analysis showed
that self-reported adequate prophylaxis and being a partially immune traveller visiting friends and relatives was
associated with significantly lower odds ratio of severe malaria. In contrast, age, acquisition of malaria in West-Africa
and being a non-immune tourist increased their risk significantly.
Conclusions: Compliant use of malaria chemoprophylaxis was associated with significantly lower odds ratios for
severe malaria as compared with non-compliant users and non-users of chemoprophylaxis. After correction for age,
gender and immunity, this protective effect of malaria chemoprophylaxis was present only in individuals who
adhered compliantly to use of chemoprophylaxis. Patients with P. falciparum malaria were more likely to have used
their chemoprophylaxis less compliantly than patients with non-P. falciparum malaria who were more likely to have
contracted malaria in spite of compliant use of chemoprophylaxis.
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Malaria is a mosquito-transmitted disease which may
cause a wide variety of symptoms, ranging from no or
mild symptoms to severe disease and death. The clinical
features and outcome measures of malaria are thought
to depend on the infecting Plasmodium species, the im-
mune status of the patient, prior use or non-use of
chemoprophylaxis, and the timeliness and nature of any
treatment administered. Even though the global burden
of malaria is largely carried by the world’s malaria-
endemic regions with as many as 500 million cases an-
nually and a death toll of one million children each year,
malaria may also be acquired by international travellers
from non-endemic areas [1]. Every year between 10,000
and 30,000 of these travellers fall ill with malaria after
returning home [2]. Estimates indicate that around 150
returning travellers die each year from imported malaria,
usually due to Plasmodium falciparum infection [1].
Malaria can be prevented through a range of barrier
measures to prevent mosquito bites and by taking che-
moprophylactic drugs. In areas of intense malaria trans-
mission, malaria chemoprophylaxis remains the most
important strategy for preventing malaria in travellers
[3], but its use may be associated with adverse outcomes
and even death [4]. These potentially severe adverse ef-
fects may undermine compliant use of malaria chemo-
prophylaxis in travellers, in particular when considering
that these travellers were usually healthy when commen-
cing travel [5-9]. An additional difficulty with malaria
chemoprophylaxis is that all drug regimens must be
taken meticulously during and for one or more weeks
after leaving the malaria-endemic area [10]. The compli-
ant use of malaria chemoprophylaxis therefore requires
considerable personal discipline. Unfortunately, a sub-
stantial proportion of travellers may discontinue their
anti-malarial drugs soon after returning home because
continuation of these drugs after travel may feel counter-
intuitive [11]. Inappropriate use or early discontinuation
of chemoprophylaxis is likely to be a key element in ma-
laria acquisition, but might, speculatively, also worsen
the severity of imported cases. In the present study the
impact of (self-reported) adherence to malaria chemo-
prophylaxis on clinical features and outcome of im-
ported malaria was compared to those who reported less
compliant use or did not use malaria chemoprophylaxis
at all.
Methods
The Harbour Hospital is a 161-bed general hospital lo-
cated in Rotterdam, The Netherlands. It also comprises
the Institute for Tropical Diseases, which serves as a
national referral centre. The Rotterdam Malaria Cohort
consists of all patients diagnosed with malaria at the
Institute for Tropical Diseases in Rotterdam. In theperiod 1998–2011 the Rotterdam Malaria Cohort com-
prised 604 cases of imported malaria. All patients’ demo-
graphic, clinical and laboratory data are systematically
collected and stored in an electronic database after de-
identification. For the present study, data from patients
who entered the Rotterdam Malaria Cohort between
June 1998 and December 2011 were used to estimate
the impact of use of malaria chemoprophylaxis on clin-
ical and laboratory features of imported malaria as well
as on the outcome of imported malaria. The outcome
measures of interest were: severity of malaria, time in
hospital, admission to intensive care unit (ICU), mecha-
nical ventilation, renal replacement therapy, exchange
transfusion and death. All available laboratory data
were measured on admission with the use of routine
procedures.
The standard procedure to diagnose malaria com-
prised a quantitative buffy coat (QBC) analysis, a rapid
diagnostic test (RDT) for malaria antigens Binax NOW®
Malaria Test (Binax, Inc, Maine, USA), and thick and
thin blood smears using freshly collected blood speci-
mens from finger pricks. The malaria rapid test and the
QBC analysis were performed according to the manufac-
turer’s instructions. QBC capillaries were examined inde-
pendently by two technicians by microscopic analysis of
two complete rows of the region between the bottom of
the capillary and the poly-nuclear leukocyte layer using
an Olympus BX-60 fluorescence microscope equipped
UV-filter and 50x objective and 12.5x oculars (total mag-
nification 625x). Thick blood smears were stained with
Field’s stain (Brunschwig Chemie, Amsterdam, The
Netherlands) and thin smears were fixed with absolute
methanol for three minutes and stained with Diff Quick
(Medion Diagnostics, Düdingen, Switzerland). Both stai-
ning procedures had been optimized for optimal staining
of Plasmodium parasites as well as Schüffner’s dots and
Maurer’s clefts in infected erythrocytes. Thick and thin
smears were examined with regular light microscopes at
a total magnification of 1,250x.Definitions
Severe malaria
Patients were considered as having severe P. falciparum
malaria if they met the 2010 World Health Organization
(WHO) criteria for severe malaria on admission or du-
ring hospitalization [12]. These criteria differ from the
preset criteria [13] that were used to define severe ma-
laria in previous studies for the Rotterdam Malaria
Cohort [14].Use of malaria chemoprophylaxis
Compliant use of malaria chemoprophylaxis was defined as
self-reported compliant use of malaria chemoprophylaxis,
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health advice regarding malaria chemoprophylaxis (www.
lcr.nl). In case the patient did not adhere compliantly to
these Dutch guidelines, the use of chemoprophylaxis was
classified as non-compliant. Travellers not using any drug
for chemoprophylaxis of malaria were labelled as non-
users.
Estimation of immunity to malaria
The degree of immunity to malaria was estimated as fol-
lows [15]. Adult immigrants from a malaria-endemic
country living in The Netherlands were considered par-
tially immune, because they had likely been exposed to
P. falciparum during childhood. Immigrant patients who
had been born, raised and living in a malaria-endemic
area at the time of diagnosis were presumed semi-
immune. However, given the relatively low number of
semi-immune persons in the Rotterdam Malaria Cohort
[15], they were grouped with partially immune individ-
uals. Tourists from non-endemic regions who travelled
to endemic areas were considered non-immune.
Statistical analysis
Data were entered into an Excel database and reviewed
for inconsistencies. IBM SPSS statistics 19 (IBM inc,
Chicago, IL, USA) was used for statistical analysis, using
Chi-square tests for binary outcomes and Kruskal-Wallis
analysis to compare continuous variables. Dunn’s post-
hoc calculations were performed using GraphPad Instat
3.0 in case of a significant Kruskal-Wallis result. Uni-
variate and multivariate logistic regression was used to
assess the impact of several variables on the outcome
parameter severe malaria. P. falciparum parasite load
was not entered as an explanatory variable in the univar-
iate and multivariate analyses of predictors for severe
disease, because parasite load is – by definition - one of
the defining criteria of severe P. falciparum malaria. A
P-value of less than 0.05 was considered to represent a
statistically significant difference.
Ethical approval
Given its retrospective observational design, ethical ap-
proval of this study was not required, according to the
Dutch Medical Research Involving Human Subjects Act.
Results
Clinical and laboratory features of malaria patients on
admission
For 559 of 604 (92.5%) malaria patients included in the
Rotterdam Malaria Cohort, details of prophylaxis use
were available. The general characteristics of these 559
patients are shown in Table 1. Three hundred and sixty-
one (64.6%) malaria patients did not use any form of
malaria chemoprophylaxis, 100 (17.9%) used malariaprophylaxis inadequately whereas 98 (17.5%) patients
presented with malaria despite adequate use of malaria
chemoprophylaxis. Ethnicity differed significantly bet-
ween the three prophylaxis groups with Caucasians be-
ing over-represented in the adequate prophylaxis group.
African ethnicity was more common in the group of pa-
tients not using malaria chemoprophylaxis. When im-
munity status towards malaria was estimated, the group
of patients without chemoprophylaxis was predominated
by patients with presumed partial immunity. The pre-
sumed immune status of the majority of adequate users
of malaria chemoprophylaxis was non-immune (Table 1).
With regard to purpose of travel, tourists comprised a
substantial proportion of the adequate users group,
whereas the group of non-users was dominated by visit-
ing friends and relatives (VFRs) and sailors. There were
no significant differences in seasons of travel. The ma-
jority of the non-users contracted malaria in Africa,
whereas almost half of the patients with compliant use
of chemoprophylaxis contracted malaria outside of Africa.
Vital signs on admission did not differ between the three
patient groups. Admission C-reactive protein and creatin-
ine levels were significantly higher in non-users as com-
pared with compliant users (Table 1).
Outcome of malaria patients
Patients with compliant use of malaria chemoprophylaxis
had significantly lower odds ratios for the outcome par-
ameter severe malaria (OR 0.121 (95% CI 0.029-0.516)
than patients not using malaria prophylaxis (Table 2,
Figure 1). In addition, patients with compliant use of ma-
laria chemoprophylaxis also had lower odds ratios for ad-
mission to ICU and shorter times in hospital (Table 2).
Also in univariate and subsequent multivariate analyses,
age, region of acquisition, adequate use of malaria chemo-
prophylaxis as well as non-immune tourists and partially
immune VFRs were identified as independent predictors
for severe malaria (Table 3). Interestingly, non-immune
tourists had significant higher odds ratios whereas par-
tially-immune VFRs had significantly lower odds ratios
for severe malaria. The combined variables non-immune
tourists and partially immune VFRs were used to diminish
the number of variables in the multivariate analyse but
also to partially negotiate for the (confounding) inter-
action between non-immunity and tourists on one hand
and partially-immunity and VFRs on the other hand.
Causative Plasmodium species in relation to use of
malaria chemoprophylaxis
The distribution of the causative Plasmodium species in
relation to the use of and adherence with malaria che-
moprophylaxis is shown in Figure 2. The majority of the
Plasmodium species in malaria patients who did not use
malaria chemoprophylaxis or did not compliantly adhere
Table 1 General characteristics of malaria patients entered in the Rotterdam Malaria Cohort grouped according to
self-reported adherence with malaria chemoprophylaxis
Non-users Non-compliant users Compliant users P-values
n = 361 n = 100 n = 98
Demographics
Age, years 39 (5–70) 37 (13–60) 38 (4–77) N.S.
Gender, n (%) N.S.
Male 263 (73) 73 (73) 62 (63)
female 98 (27) 27 (27) 36 (37)
Ethnicity, n (%) <0.001
Caucasian 148 (42) 64 (65) 78 (80)
African 160 (45) 31 (31) 14 (14)
Asian 32 (22) 3 (5) 3 (3)
Other 16 (10) 1 (3) 3 (3)
Immunity, n (%) <0.001
Non immune 138 (49) 50 (64) 30 (81)
Partially immune 139 (61) 28 (36) 7 (19)
Travel history
Reason for travel, n (%) <0.001
Tourist 69 (21) 28 (30) 35 (51)
VFR 114 (35) 27 (29) 11 (16)
Business 54 (17) 27 (29) 15 (22)
Expat 25 (8) 4 (4) 3 (4)
Sailor 37 (11) 3 (3) 4 (6)
Other 24 (7) 4 (4) 1 (1)
Continent of infection, n (%) <0.001
African 290 (82) 82 (82) 54 (58)
Asian 42 (12) 10 (10) 22 (24)
Americas 19 (5) 7 (7) 14 (15)
Other 1 (0) 1 (1) 3 (3)
Duration of complaints, n (%) N.S.
Less than 8 days 228 (63) 70 (70) 46 (47)
8–14 days 66 (18) 18 (18) 21 (21)
15–21 days 25 (7) 6 (6) 6 (6)
>28 days 9 (3) 5 (5) 2 (2)
Unknown 34 (9) 1 (1) 23 (24)
n = 361 n = 100 n = 98
Vital signs
Temperature, °Celsius 38.5 (35.0–41.5) 38.8 (36.1–40.9) 38.5 (36.0–41.2) N.S.
Systolic blood pressure, mmHg 120 (64–185) 123 (90–190) 120 (90–196) N.S.
Pulse rate, beats per minute 92 (50–150) 94 (56–130) 96 (60–150) N.S.
Laboratory features
Haemoglobin, mmol/L 8.3 (2.5–11.0) 8.3 (4.0–11.1) 8.4 (4.2–10.7) N.S.
Thrombocytes, x109/L 84 (2–293) 99 (3–302) 96 (19–258) N.S.
Leucocyte count, x109/L 5.3 (1.3–18.5) 5.1 (1.9–13.4) 5.0 (1.5–12.9) N.S.
CRP, mg/L 96 (5–476) 77 (7–310) 71 (6–287) 0.0009 A: p<0.01, B: p<0.05
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Table 1 General characteristics of malaria patients entered in the Rotterdam Malaria Cohort grouped according to
self-reported adherence with malaria chemoprophylaxis (Continued)
Creatinine, μmol/L 93 (39–1.081) 95 (55–213) 87 (46–405) 0.0019 B: p<0.01, C: P<0.01
LDH, U/L 265 (103–2.297) 270 (98–877) 237 (98–664) N.S.
Bilirubin, μmol/L 24 (3–416) 22 (6–95) 23 (5–262) N.S.
Lactate, mmol/L 1.6 (0.5–6.2) 1.6 (0.5–4.7) 1.3 (1.1–1.8) N.S.
Legend: n = 559. Data are given as median (range) or number (%), as appropriate.
A: No prophylaxis versus inadequate prophylaxis, B: no prophylaxis versus adequate prophylaxis, C: inadequate prophylaxis versus adequate prophylaxis,
N.S. not statistically significant.
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arum. In contrast, non-P. falciparum species were iden-
tified as the causative species of malaria in the majority
of malaria patients who used malaria chemoprophylaxis
compliantly (Figure 3). In fact, of the group of malaria
patients who reported use of malaria chemoprophylaxisTable 2 Outcome measures of patients with malaria, grouped
chemoprophylaxis
Outcome measure Group Proport
mean (9
Severe malaria No chemoprophylaxis 53/361
(WHO 2010) Non-compliant use 8/100
Compliant use 2/98
ICU admission No chemoprophylaxis 73/361
Non-compliant use 15/100
Compliant use 6/98
Mechanical ventilation No chemoprophylaxis 3/361
Non-compliant use 1/100
Compliant use 0/98
Renal replacement therapy No chemoprophylaxis 7/361
Non-compliant use 0/100
Compliant use 0/98
Exchange transfusion No chemoprophylaxis 35/361
Non-compliant use 6/100
Compliant use 1/98
Death No chemoprophylaxis 2/361
Non-compliant use 0/100
Compliant use 0/98
P. falciparum species No chemoprophylaxis 285/358
Non-compliant use 77/100
Compliant use 41/98
P. falciparum parasite load
(asexual parasites per μL)
No chemoprophylaxis 73,774 (
Non-compliant use 48,866 (
Compliant use 24,563 (
Time in hospital (days) No chemoprophylaxis 4.8 (4.4–
Non-compliant use 4.8 (4.4–
Compliant use 2.9 (2.4–
Legend: * = 3 patients with a mixed P. falciparum/non-falciparum infection were exc(either compliantly or non-compliantly), patients with P.
falciparum malaria had significantly higher odds ratio
for non-compliant use than patients who presented with
non-P. falciparum malaria (Table 4, Figure 3). At the
level of specified drug use, this observation was also
valid in atovaquone-proguanil and mefloquine users butaccording to self-reported adherence with malaria
ion or
5% CI)






























luded, CI confidence interval, N.A. not applicable, N.S. not statistically significant.
Figure 1 Outcome of malaria patients in the Rotterdam Malaria
Cohort in relation to self-reported use of malaria
chemoprophylaxis. Legend: * = including the two fatal cases.







Partially or semi immune 0












Season of infection March-August 0
September-February 0
Prophylaxis Adequate prophylaxis 0
Inadequate prophylaxis 0
No prophylaxis 0
Duration of illness before diagnosis 1 to 7 days 0
8 to 14 days 0
15 to 28 days 0
More than 28 days 0
Combined variables Non-immune tourists 0
Partially-immune VFR 0
Legend: Included n = 559, CI confidence interval, VFR visiting friends and relatives, N
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patients who presented with non-P. falciparum species
were more likely to have contracted malaria in spite of
compliant use of chemoprophylaxis (Table 4, Figure 3).
Causative Plasmodium species in relation to outcome
severe malaria
Even though the occurrence of severe malaria is not
explicitly confined to P. falciparum species alone and se-
vere cases of non-P. falciparum have been recognized
(especially in cases with P. vivax and P. knowlesi in-
fections), all cases of severe malaria in the Rotterdam
Malaria Cohort were associated with P. falciparum in-
fections. For this reason, the univariate and multivariate
statistical analysis was also done separately for malaria
patients with infections solely caused by P. falciparumdictors for severe malaria
Univariate analysis Multivariate analysis
alue Odds ratio (95% CI) P-value Odds ratio (95% CI)
.000 1.048 (1.024–1.071) 0.003 1.037 (1.013–1.062)


















.006 0.137 (0.033–0.569) 0.007 0.132 (0.031–0.567)






.000 3.274 (1.770–6.058) 0.026 2.200 (1.101–4.396)
.059 0.476 (0.221–1.029) 0.045 0.426 (0.185–0.981)
.A. not applicable.
Figure 2 Distribution of Plasmodium species diagnosed in the
Rotterdam Malaria Cohort in relation to self-reported use of
malaria chemoprophylaxis. Note that the total number of people
without prophylaxis is higher due to three mixed infections.
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of acquisition, adequate use of malaria chemoprophy-
laxis and the combined variable partially-immune VFR
were again identified as independent predictors for se-
vere (P. falciparum) malaria but the combined variable
non-immune tourists lost its statistical significance due
to the reduction in number of eligible cases.Discussion
Deaths from malaria among travellers are known to be
related to delays in treatment and failure to comply with
anti-malarial chemoprophylaxis [16]. Both case fatalities
in the current study occurred in patients not taking
chemoprophylaxis. However, statistical analysis did not
reveal a significant difference in case-fatality rates between
compliant users, non-compliant users and non-users,
which was conceivably due to the very low number of case
fatalities in the Rotterdam Malaria Cohort.Figure 3 The proportion of compliant versus non-compliant use of sp
presenting with P. falciparum malaria, B: in patients presenting with non-P.
MQ=mefloquine; C-P = chloroquine-proguanil.Evidence is accumulating that severe P. falciparum
malaria tends to occur more commonly in patients not
taking malaria chemoprophylaxis [17]. This may be par-
ticularly true for the non-immune traveller to malaria-
endemic regions, especially elderly persons [18,19] as
became also evident from the current study. Compliant
use of anti-malarial chemoprophylaxis was associated
with a significantly lower odds ratio for severe malaria.
In addition, compliant users of chemoprophylaxis with
malaria had significantly lower P. falciparum loads on
admission as compared to those who took no chemo-
prophylaxis at all or did not comply with proper use.
This reduced parasite burden in compliant users of
chemoprophylaxis probably directly relates to a decrease
in risk since many studies documented that high parasite
loads are independently associated with worse outcome
[18,20]. In terms of outcome, non-compliant users did
not significantly differ from non-users. The protective
effects of the currently recommended drugs for chemo-
prophylaxis of malaria was only present when taken as
indicated.
Among travellers there is also increasing evidence that
severe malaria tends to occur less frequently in people of
African origin [21,22]. This reduced risk is commonly
attributed to some degree of residual immunity towards
malaria. The findings of the present study are in line
with this. Individuals with partial immunity visiting
friends and relatives had significant lower odds of severe
malaria. Conversely, non-immune tourists had signifi-
cant higher odds for severe malaria and a more compli-
cated course. Even when the protective effects of partial
immunity and the risk of non-immunity were taken into
account in the multivariate analysis, the protective effect
of compliant use of chemoprophylaxis on odds for se-
vere malaria remained present as an independent factor.
This suggests that partially immune VFRs may further
reduce their risk for severe malaria by strict adherenceecified chemoprophylaxis in patients with malaria. A: in patients
falciparum malaria. Legend: A-P = atovaquone-proguanil;




The odds ratio for non-compliant
use of prophylaxis in P. falciparum
infections versus non-P. falciparum
infections
Drug used for chemoprophylaxis Malaria species Non compliant (n = 100) Compliant (n = 98) P-value Odds ratio (95% CI)
Atovaquone-proguanil P. falciparum 7 3
0.024 7.778 (1.200–50.424)
Non-falciparum 3 10
Mefloquine P. falciparum 33 7
<0.001 11.000 (3.556–34.023)
Non-falciparum 9 21
Chloroquine-proguanil* P. falciparum 12 15
0.236 2.800 (0.489–16.036)
Non-falciparum 2 7
Others P. falciparum 25 16
0.019 3.299 (1.200–9.069)
Non-falciparum 9 19
Total P. falciparum 77 41
<0.001 4.654 (2.517–8.607)
Non-falciparum 23 57
Legend: N.A. not applicable, CI confidence interval, * = chloroquine-proguanil combination only.
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with other studies [19], increasing age was also in the
current study identified as an independent risk factor for
a worse outcome. Pre-travel health advice should stress
the importance of compliant use of chemoprophylaxis in
each traveller but – given their risk profile [23] - particu-
larly in elderly travellers, non-immune tourists and last-
minute-travellers [19,23].
In areas of intense malaria transmission, malaria che-
moprophylaxis remains the most important strategy for
prevention of malaria in non-immune travellers. A re-
cent Cochrane review, however, provided inconclusive
evidence about which of the currently recommended
drugs atovaquone/proguanil, mefloquine and doxy-
cycline, was most effective in preventing malaria in
non-immune populations travelling to regions with P.
falciparum resistance to chloroquine [24]. Interestingly,
occasional failures of anti-malarial chemoprophylaxis
have been documented for any chemoprophylactic regi-
men [25-27]. The current findings of the acquisition of
malaria by travellers despite compliant use of malaria
chemoprophylaxis underline these potential restrictions.
Even though it can not be excluded that resistance pat-
terns towards the commonly used chemoprophylactic
drugs might have changed over time during the course
of this study, the findings of the current study stress the
notion that the occurrence of P. falciparum malaria in a
person taking malaria chemoprophylaxis was more likely
to be associated with non-compliant than with comp-
liant use. This finding was not only demonstrable in the
whole group of malaria patients taking chemoprophylac-
tic drugs, but also valid for those individuals taking ei-
ther atovaquone/proguanil or mefloquine for prevention
of malaria, in line with their biochemical mode of action.In contrast, this differential effect was not present in
chloroquine-proguanil users, which might raise add-
itional concerns on the efficacy of chloroquine-proguanil
for prevention of P. falciparum malaria. In contrast, the
occurrence of non-P. falciparum malaria in a subject
taking malaria chemoprophylaxis was more likely to
occur in spite of compliant use of a chemoprophylactic
drug. This observation is not surprisingly since the la-
belled indication of chemoprophylactic anti-malarials is
to prevent the acquisition of P. falciparum malaria only
[25-27].
Limitations
A major limitation of any retrospective analysis is that
data were not originally recorded with this type of study
in mind. In addition, there is no exact information about
the total number of travellers that were at risk of malaria
and their compliance with regard to prophylaxis during
the study period. This limits the outcomes to odds ratios
instead of relative risks. Further, one could argue that
estimating the degree of compliance, especially self-
reported compliance, may have introduced an important
selection and recall bias. Previous studies compar-
ing self-reported compliance with prophylactic anti-
malarials and measurements of blood levels showed that
patients significantly overestimated their degree of com-
pliance [28]. However, even within the framework of
these limitations, the parameter self-reported compli-
ance with malaria chemoprophylaxis should be consid-
ered a valuable asset for clinical decision making and
risk assessment. With the use of the current straightfor-
ward clinical criteria for compliant and non-compliant
use of malaria chemoprophylaxis, only compliant use of
malaria chemoprophylaxis was identified as an independent
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risk of severe malaria. These protective effects remained
present after adjustment for the potentially confounding
protective effects of partial immunity and being a VFR
traveller. Of note, these protective effects of anti-malarial
chemoprophylaxis were not demonstrable for non-
compliant users.
Conclusions
Compliant use of malaria chemoprophylaxis was associ-
ated with significantly lower odds ratios for the occur-
rence of severe malaria and admission to ICU. These
protective effects of malaria chemoprophylaxis on out-
come of malaria were only present when malaria chemo-
prophylaxis was taken as indicated. Increasing age,
acquisition of malaria in West Africa and being a non-
immune tourist were identified as independent predic-
tors associated with an increased risk of severe malaria.
Partially immune individuals, in particular those visiting
friends and relatives had significantly lower odds ratios
for severe malaria. These important protective effects of
compliant use of malaria chemoprophylaxis should be
stressed in future pre-travel health encounters with tra-
vellers to tropical regions, especially with presumed non-
immune and elderly travellers.
Additional file
Additional file 1: Univariate and multivariate logistic regression of
predictors for severe P. falciparum malaria.
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